Bill C-286

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

First Reading

Bilingual view XML PDF

SUMMARY
1 Purpose of the Act
2 Amendments
2 Controlled Drugs and Substances Act
3 Food and Drugs Act

First Session, Forty-fifth Parliament,

3-4 Charles III, 2025-2026

HOUSE OF COMMONS OF CANADA

BILL C-286
An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act

FIRST READING, June 16, 2026

Mr. Tochor

451195

SUMMARY

This enactment amends the Controlled Drugs and Substances Act and the Food and Drugs Act to allow psilocin and psilocybin to be used for medical treatment in accordance with the Narcotic Control Regulations. It also provides for the automatic approval of requests for priority review for certain new drugs.

Available on the House of Commons website at the following address:

www.ourcommons.ca

1st Session, 45th Parliament,

3-4 Charles III, 2025-2026

HOUSE OF COMMONS OF CANADA

BILL C-286

An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act

His Majesty, by and with the advice and consent of the Senate and House of Commons of Canada, enacts as follows:

Purpose of the Act

1 The purpose of this Act is to improve access to hallucinogenic drug medical treatment and not to circumvent existing approval processes for new drugs.

Amendments

1996, c. 19

Controlled Drugs and Substances Act

2 Section 2 of the Controlled Drugs and Substances Act is amended by adding the following after subsection (3):

Definition of narcotic

(4) For the purposes of the Narcotic Control Regulations, narcotic means

(a) psilocin (3-[2-(dimethylamino)ethyl]-4-hydroxyindole) and any of its salts;
(b) psilocybin (3-[2-(dimethylamino)ethyl]-4-phosphoryloxyindole) and any of its salts;
(c) a controlled substance set out in the schedule to the Narcotic Control Regulations; or
(d) in respect of a midwife, nurse practitioner or podiatrist, a controlled substance set out in the schedule to the Narcotic Control Regulations that the midwife, nurse practitioner or podiatrist may prescribe, possess or conduct an activity with, in accordance with sections 3 and 4 of the New Classes of Practitioners Regulations.
End of inserted block

Definition of restricted drug

(5) For the purposes of Part J of the Food and Drug Regulations, restricted drug means a controlled substance that is set out in the schedule to that Part and that is not psilocin (3-[2-(dimethylamino)ethyl]-4-hydroxyindole) or any of its salts, or psilocybin (3-[2-(dimethylamino)ethyl]-4-phosphoryloxyindole) or any of its salts.

R.‍S.‍, c. F-27

Food and Drugs Act

3 Section 2 of the Food and Drugs Act is renumbered as subsection 2(1) and is amended by adding the following:

Definition of restricted drug

(2) For the purposes of Part J of the Food and Drug Regulations, restricted drug means a controlled substance that is set out in the schedule to that Part and that is not psilocin (3-[2-(dimethylamino)ethyl]-4-hydroxyindole) or any of its salts, or psilocybin (3-[2-(dimethylamino)ethyl]-4-phosphoryloxyindole) or any of its salts.

4 The Act is amended by adding the following after section 15:

New Drug Submission

Priority review status

15.‍1 A request for priority review status that is submitted to the Department respecting a new drug submission in accordance with the Priority Review of Drug Submissions Policy, adopted by the Department on December 13, 1996, as amended from time to time, is deemed to have been granted by the Department on the day on which it receives the request if the request is for

(a) psilocin (3-[2-(dimethylamino)ethyl]-4-hydroxyindole) or any of its salts;
(b) psilocybin (3-[2-(dimethylamino)ethyl]-4-phosphoryloxyindole) or any of its salts; or
(c) any substance that has a chemical structure substantially similar to that of a substance referred to in paragraph (a) or (b).
End of inserted block

Published under authority of the Speaker of the House of Commons